The sensitivity and specificity of each tumor marker (CA19‐9, CA‐125 and CEA) in borderline or malignant mucinous ovarian tumor for CA19‐9 were 52.7% and 83.8%, CA‐125 were 68.2% and 83.9%, CEA were 31.9% and 90.8%, respectively. This evidence concerns the gene MUC16 and ovarian mucinous neoplasm.